Princess Margaret Cancer Centre

The 2017 OneWalk to Conquer Cancer benefiting Princess Margaret Cancer Centre

The 2016 Rexall OneWalk to Conquer Cancer raised $6.5 million. Since 2003, supporters of The Princess Margaret have walked to help conquer cancer in all its forms. To date over $162 million has been raised. 2017 celebrates 15 years of walking to conquer cancer.

Funds raised through the Rexall OneWalk to Conquer Cancer support Personalized Cancer Medicine at The Princess Margaret, enabling world-leading clinicians and researchers to detect cancers earlier, diagnose with more precision, target treatment for each patient and support patients and their families throughout the cancer journey. Princess Margaret Cancer Centre is leading the way in Personalized Cancer Medicine as one of the top 5 cancer research centres in the world.

With OneWalk you choose to fundraise as a team or individually and you designate the fundraising dollars to support the cancer fund that matters most to you.

When a participant registers, they select a cancer fund to support, such as: Discovery Research, Breast, Gynaecologic, Lung, Gastrointestinal, Hepatobiliary, Genitourinary, Blood Cancers, Endocrine, Skin Cancer and Melanoma, Head and Neck Cancers, Central Nervous System Cancers, Brain and Eye Cancer, Sarcoma, Childhood Cancers, Supportive Care, Patient Education, and Radiation Medicine.

Princess Margaret Cancer Centre is one of the top 5 cancer research centres in the world. The Princess Margaret has the largest cancer research and clinical program in Canada. As global leaders in cancer care, The Princess Margaret has the expertise to treat over 200 types of cancers, including the rarest forms of the disease.

The Princess Margaret has a rich history of research excellence, discovery and innovation. Every day, oncologists at The Princess Margaret combine clinical strength with the research expertise of The Campbell Family Cancer Research Institute to deliver breakthrough cancer research, treatments and patient-centred care.

As Canada’s largest and most comprehensive cancer research centre, The Princess Margaret is responsible for delivering the evidence and measuring the benefit of new treatments and new approaches. The Princess Margaret is proud to lead the way in the creation and delivery of the new gold standard in cancer care: Personalized Cancer Medicine.

This new model of patient care will allow The Princess Margaret to detect cancer earlier, diagnose cancer with more precision, target treatment more effectively and support patients and families through their cancer journey. By leveraging research and clinical strength, The Princess Margaret will continue to lead the way and deliver the evidence that will create Personalized Cancer Medicine for patients at The Princess Margaret, across Canada and around the world.

The new discoveries and innovative cancer therapies that are changing cancer care for patients globally are happening right here in Canada, at The Princess Margaret.

The Princess Margaret is...

  • the world leader in cancer stem cell research
  • a world leader in image-guided therapeutics
  • a world leader in lung cancer research and treatment
  • a world leader in patient survivorship program development
  • an emerging leader in breast cancer research and discovery

2014 2015 By the Numbers (approx average based on 5 day week):
Princess Margaret Cancer Centre treats over 200 types of cancer through surgery, chemotherapy, radiation, psychosocial and palliative care.

  • New patients: 18,003
  • Outpatient chemo visits: 34,851
  • Radiation visits: 93,379
  • Outpatient Clinic visits/day*: 1,652
  • Stem cell transplants: 416
  • Surgeries: 6,206

Funds raised since 2003 have powered a range of cancer research, clinical enhancements survivorship and other programs at Princess Margaret Cancer Centre.

  • $54.7 million to The Campbell Family Institute for Breast Cancer Research led by Dr. Tak Mak, with 11 Principal Investigators and over 130 staff.
    • Dr. Tak Mak and his team of researchers from The Campbell Family Research Institute announced a new “sharpshooter” cancer drug that will target an enzyme called PLK4, which plays a crucial role in the process of cancer cell division. On July 18, 2013 Dr. Mak and his team gained clearance by Health Canada to proceed with the drug into Phase I Clinical Trial in Canada.*
    • Scientists led by Drs. Mona Gauthier and Tak Mak have discovered how BRCA1 gene mutations specifically predispose women to breast and ovarian cancers.
    • Dr. Pamela Ohashi’s research into T-cell activation and boosting the immune system to fight tumors. Her work focuses on understanding the signaling pathways of T-cells to help activate, direct and enhance anti-tumor responses in cancer. Clinical trial of her team’s adoptive cell therapy began in the Fall of 2013. Dr. Pamela Ohashi’s research into T-cell activation and immunotherapy to fight breast tumours, is part of The Campbell Family Institute funding.
  • $7.4 million to purchase cutting edge research equipment and support breast cancer research activities in the PMH research expansion at MaRS (Medical and Related Science).
  • $3 million to create The Weekend to End Breast Cancer Chair in Breast Cancer Research, held by Dr. Tak Mak, a world renowned cancer research scientist.
  • $1.5 million to the Walker Innovation Program, which supports researchers and new ideas that have the potential for advancing scientific knowledge of breast cancer.
  • $2.1 million to support Dr. Norman Boyd’s research into breast cancer prevention, focusing on the understanding of mammographic density as a risk factor.
  • $1.8 million to support Mass Spectrometer program
  • $500,000 to support research at The Campbell Family Cancer Research Institute for equipment, lab expenses, research and staff related expenses and research operations.
  • $3.9 million toward a comprehensive breast imaging program and the purchase of a breast MRI and digital mammography machine.
  • $3 million toward a newly revamped and re-designed M. Lau Breast Centre that provides complete care for breast cancer patients.
  • $2.9 million to support clinical trials for breast cancer patients. and $500,000 for fellowship program
  • $2 million to support an extensive Tumour Bank, database maintenance and pathology renovations.
  • $1.3 million to support Dr. David McCready’s rapid diagnosis pilot study, which is now The Gattuso Rapid Diagnostic Centre and sees up to 1,500 patients a year.
  • $550,000 to support the clinical trial of intraoperative radiation therapy, led by Dr. David McCready and Dr. Anthony Fyles.
  • $250,000 toward the design and creation of the new Conway Chemotherapy and Transfusion Centre, the largest centre of its kind in North America.
  • $880,000 to support the surgical robotics program for gynaecologic cancer patients.
  • $160,000 toward the Familial Ovarian Cancer Clinic, which now also provides genetic counselling for breast cancer patients.
  • $3.4 million for other clinical enhancements and genetics research programs
  • $2.5 million to support Princess Margaret’s Space Transformation which is a multi-phase project that will create a transformative environment for Personalized Cancer Medicine.
  • $130,000 towards grant matching program
  • $11 million for the establishment and continued support of the first in-hospital Survivorship Clinic and Program in Canada. This includes ELLICSR, a 12,000-square-foot innovative research centre, and caringvoices.ca, an award-winning online community for survivors and their families.
  • $1 million to provide reconstructive breast surgery for women who have had breast cancer.
  • $3.1 million to support the Princess Margaret Cancer Foundation Fund

*New cancer drug development is a long and risk-filled process. We are very encouraged by this discovery and reaching this major milestone. The drug discovery from Dr. Tak Mak and Dr. Dennis Slamon announced by The Princess Margaret Cancer Foundation in June 2013 has been cleared by Health Canada and the University Health Network Research Ethics Board, and is in clinical trials. For more information please visit www.canadiancancertrials.ca.

To achieve global impact, a scientific research institute requires world-class people, platforms and programs. The Campbell Family Cancer Research Institute at Princess Margaret Cancer Centre is fortunate that many top scientists have left their homes to come to Toronto because they believe that this is where they can have the most impact.

The Institute is building world-class research programs utilizing our expertise in the scientific platforms most vital for cancer research: mass spectrometry, flow cytometry, new drug discovery, genetic sequencing, biobanking and computational biology.

Breast cancer is the second leading cause of cancer death in Canadian females, accounting for 13 per cent of all female cancer deaths. 1 in 8 Canadian women are expected to develop breast cancer in their lifetime and 1 in 31 will die from it.

In 2017, it is estimated that:

  • 1,550 Canadian women will be diagnosed with cervical cancer
  • 7,300 will be diagnosed with uterine cancer
  • 2,800 will be diagnosed with ovarian cancer

The most recent incidence statistics for other and unspecified female genital organ cancers are from 2013:

  • 955 Canadian women were diagnosed with other and unspecified female genital organ cancers

The most recent mortality statistics for other and unspecified female genital organ cancers are from 2013:

  • 280 Canadian women died from other and unspecified female genital organ cancers

Colon, Rectal and Gastrointestinal Cancers

26,800 Canadians will be diagnosed with colorectal cancer in 2017, representing approximately 13 per cent of all new cancer cases in 2017.

  • 14,900 men will be diagnosed with colorectal cancer and 5,100 will die from it.
  • 11,900 women will be diagnosed with colorectal cancer and 4,300 will die from it

It is estimated that in 2017, 3,500 Canadians will be diagnosed with stomach cancer.

  • 2,200 men will be diagnosed with stomach cancer and 1,250 will die from it.
  • 1,300 women will be diagnosed with stomach cancer and 790 will die from it.

The five-year relative survival for stomach cancer is 25 per cent. This means that, on average, people diagnosed with stomach cancer are 25 per cent as likely to live 5 years (or more) after diagnosis as people in the general population who do not have cancer.

Prostate, Testicular, Bladder, Kidney and Genitourinary Cancers

Prostate Cancer:

21,300 men will be diagnosed with prostate cancer. This represents 21 per cent of all new cancer cases in men in 2017. 4,100 men will die from prostate cancer. This represents 10 per cent of all cancer deaths in men in 2017.

  • On average, 58 Canadian men will be diagnosed with prostate cancer every day
  • On average, 11 Canadian men will die from prostate cancer every day

Prostate cancer is the most common type of cancer among Canadian men, excluding non-melanoma skin cancer.

Testicular Cancer:

  • An estimated 1,100 Canadian men will be diagnosed with testicular cancer in 2017
  • An estimated 45 will die from the disease

Bladder:

It is estimated that in 2017:

  • 8,900 Canadians will be diagnosed with bladder cancer and 2,400 Canadians will die from bladder cancer
  • 6,700 men will be diagnosed with bladder cancer and 1,700 will die from it
  • 2,200 women will be diagnosed with bladder cancer and 680 will die from it

Kidney Cancer:

It is estimated that in 2017, 6,600 Canadians will be diagnosed with kidney cancer.

  • 4,200 men will be diagnosed with kidney cancer and 1,200 will die from it
  • 2,400 women will be diagnosed with kidney cancer and 670 will die from it

It is estimated that in 2017:

  • 5,500 Canadians will be diagnosed with pancreatic cancer
  • 4,800 Canadians will die from pancreatic cancer
  • 2,800 men will be diagnosed with pancreatic cancer and 2,400 will die from it
  • 2,700 women will be diagnosed with pancreatic cancer and 2,400 will die from it

Pancreatic cancer is the fourth leading cause of cancer death in both sexes accounting for 6 per cent of all cancer deaths.

In Canada, the five-year net survival for pancreatic cancer is eight per cent. This means that, on average, about eight per cent of people diagnosed with pancreatic cancer will survive for at least five years.

Head & Neck Cancers - Brain, Central Nervous System, and Eye

It is estimated that in 2017:

  • 3,000 Canadians will be diagnosed with brain and spinal cord cancer
  • 2,400 Canadians will die from brain and spinal cord cancer
  • 1,700 men will be diagnosed with brain and spinal cord cancer and 1,350 will die from it
  • 1,300 women will be diagnosed with brain and spinal cord cancer and 1,050 will die from it
  • An estimated 55,000 Canadians are living with brain tumours

Eye cancer is rare. From 2013, approximately 335 Canadians are diagnosed with eye cancer:

  • 175 men were diagnosed with eye cancer
  • 160 women were diagnosed with eye cancer

Skin Cancer & Melanoma

It is estimated that in 2017, 7,200 Canadians will be diagnosed with melanoma.

  • 4,000 men will be diagnosed with melanoma
  • 3,300 women will be diagnosed with melanoma
  • 80-90 per cent of skin cancer cases are caused by ultraviolet radiation

Endocrine Cancer

In 2010, 135 Canadians died from endocrine system related cancers. Because these cancers are so rare, prognosis is not well known.

Lymphoma

It is estimated that in 2017:

  • 990 Canadians will be diagnosed with Hodgkin lymphoma
  • 140 Canadians will die from Hodgkin lymphoma
  • 570 men will be diagnosed with Hodgkin lymphoma and 85 will die from it
  • 430 women will be diagnosed with Hodgkin lymphoma and 60 will die from it

It is estimated that in 2017:

  • 8,300 Canadians will be diagnosed with non-Hodgkin lymphoma
  • 2,700 Canadians will die from non-Hodgkin lymphoma
  • 4,600 men will be diagnosed with non-Hodgkin lymphoma and 1,500 will die from it
  • 3,700 women will be diagnosed with non-Hodgkin lymphoma and 1,200 will die from it

Leukaemia

It is estimated that in 2017:

  • 6,200 Canadians will be diagnosed with leukaemia
  • 2,900 Canadians will die from leukaemia
  • 3,600 men will be diagnosed with leukaemia and 1,650 will die from it
  • 2,600 women will be diagnosed with leukaemia and 1,250 will die from it

Childhood cancer accounts for less than one per cent of all new cancer cases in Canada.

The three types of cancer that account for the majority of new cancer cases in children 014 years of age in Canada are:

  • Leukaemia – 32 per cent
  • Brain and central nervous system – 19 per cent
  • Lymphomas – 11 per cent

The three types of cancer that account for the majority of cancer death in children 014 years of age in Canada are:

  • Brain and central nervous system – 34 per cent
  • Leukaemia – 26 per cent
  • Neuroblastoma and other peripheral nervous cell tumours – 11 per cent

Childhood cancer is relatively uncommon. However, it remains the most common disease-related cause of death more than asthma, diabetes, cystic fibrosis and AIDS combined. It is second only to injury-related deaths among Canadian children. In 2012, cancer was the leading cause of disease-related death in children under the age of 15 years.

Between 2009 and 2013, there were 4,715 new cases of cancer in children 014 years of age in Canada, an average of 943 cases per year. Between 2008 and 2012, there were 595 cancer deaths in children 014 years of age in Canada, an average of 119 deaths per year.

An average of 290 people in Canada between the ages of 15 and 29 die from cancer each year. Young men are more likely to die than young women in this age range.

  • Radiation therapy is a critical treatment for children with cancer and The Princess Margaret has the largest paediatric radiation program in Canada
  • As a partner with SickKids, Princess Margaret Cancer Centre participates in numerous Children’s Oncology Group clinical trials and is involved in leading research in the field

Lung Cancer

It is estimated that in 2017, 28,600 Canadians will be diagnosed with lung cancer.

  • 14,400 men will be diagnosed with lung cancer
  • 14,200 women will be diagnosed with lung cancer

Sarcoma

More than half of soft tissue sarcomas begin in the arm or leg. In 2013, 1,255 Canadians were diagnosed with soft tissue sarcoma.

The Supportive Care Department at Princess Margaret Cancer Centre is an innovative global leader, supporting patients and families at all stages of the cancer trajectory. Through clinical care, research, education and international partnerships, we continue to pioneer new approaches for patients and caregivers as they cope with the impact of cancer.

With over 50 specialized staff working with each of The Princess Margaret oncology clinics, the program sees more than 2,000 patients a year. They treat physical and emotional symptoms, such as pain, depression and anxiety, and assist patients and their caregivers in managing the complexities of cancer and treatment. The program supports patients and their caregivers from the time of diagnosis, through survivorship, to the advanced stages of cancer.

Supportive Care aims to pursue continued growth and evolution in its three key areas:

  • Psychosocial Oncology
  • Palliative Care
  • Survivorship and Cancer Rehabilitation

As a global leader in patient education, The Princess Margaret offers programs that encourage and enable people with cancer, their caregivers and their families to become active participants in their cancer care. Providing an environment where patients and families feel safe to learn and ask questions is part of how we do this.

Through hospital-based services and online communities that promote self-management and improved quality of life in the hospital, at home and in the community, we help people, no matter where they are in their cancer experience, get the knowledge, skills and strategies they need to make informed decisions and healthy lifestyle choices—and cope with the many challenges that cancer brings.

We bring our expertise in health communication, adult education and theories of health behaviour change to all our Princess Margaret practitioners, working with them to develop educational resources, including patient-centred curricula, pamphlets and videos.

Our patient support includes:

  • Classes and programs
  • Community Connections
  • Patient & Family Library
  • Online education & support

Cancer is the leading cause of death in Canada and is responsible for 30 per cent of all deaths.

  • 1 out of 2 Canadians (49 per cent of men and 45 per cent of women) are expected to develop cancer during their lifetimes
  • 1 out of 4 Canadians (29 per cent of men and 24 per cent of women) is expected to die from cancer

In 2017, an estimated 206,200 new cases of cancer and 80,800 cancer deaths will occur Canada.

It is estimated that in 2017:

  • 103,100 Canadian men will be diagnosed with cancer
  • 103,200 Canadian women will be diagnosed with cancer
  • On average, 565 Canadians will be diagnosed with cancer every day

Lung, breast, colorectal and prostate cancer are the most common types of cancer in Canada (excluding non-melanoma skin cancer). Based on 2017 estimates:

  • These cancers account for over 50 per cent of all new cancer cases
  • Prostate cancer accounts for 21 per cent of all new cancer cases in men
  • Lung cancer accounts for 14 per cent of all new cases of cancer
  • Breast cancer accounts for about one-quarter (25 per cent) of all new cancer cases in women
  • Colorectal cancer accounts for 13 per cent of all new cancer cases

Source: Canadian Cancer Society

The Princess Margaret uses cutting-edge radiation technologies and has the capacity to treat over 8,000 patients every year. The Radiation Medicine Program at The Princess Margaret the largest of its kind in Canada and one of the largest in North America. A team of radiation oncologists, therapists, physicists and nurses support the assessment, planning, treatment and follow-up care for common, rare and complex forms of cancer. For more information about the Radiation Medicine Program at The Princess Margaret, click here.

Princess Margaret Cancer Centre

WHY is Princess Margaret Cancer Centre a world leader?

Your support is one reason. As the 15th year of the walk approaches, we are reminded of the thousands and thousands of women and men, who just like you, have laced up their shoes, trained, and fundraised, to walk for the Princess Margaret Cancer Centre.

The funds you and others have raised is one of the major reasons that Princess Margaret Cancer Centre is one of the top 5 cancer research centres in the world. Many of our eminent researchers would not be working at the cancer centre if not for the tremendous philanthropic support that comes from our walkers, donors, volunteers and supporters.

We believe another big reason is the intense curiosity and tenacity of our scientists and clinician researchers who never stop asking WHY—as they work with each patient, with each tumor sample, and with each new therapy. While we can’t prove it scientifically yet, our theory is that our researchers have an extra ‘WHY gene’!

The research you are supporting is helping our scientists and clinicians to find the answers and translate these insights and discoveries into innovations in patient care for Canada and the world.

With the funds and the generosity of our community of supporters, we are now in the early days of delivering on our promise of Personalized Cancer Medicine.

In 2017, Rexall™ One Walk to Conquer Cancer™ is on Saturday September 9th. This year you get to choose your distance and your impact with our 3 options: the new 15 km Celebrity Circuit; the Walker Favourite 25 km walk; or the big and bold 40 km Celebrity Challenge!

In closing, WHY do cancer patients and their families and friends want to support the research taking place at The Princess Margaret? As our Creed states “We have the momentum. We have the talent. And we have the passion.” And we never stop asking WHY—because WHY is in our DNA.

Veteran Walkers, I ask you to keep Walking. You know the impact you have made, but our battle is not over yet. First time Walkers, get ready for a Walk that will change your life.

Now is the time for all of us to Walk together, because we can’t walk away.


Sincerely,

Paul Alofs (14-year committed Walker)
President & CEO
The Princess Margaret Cancer Foundation


Thank you Walkers and Volunteers,


The 2017 Rexall™ One Walk to Conquer Cancer™ will be a historic point in the journey as this is the Walk’s 15th year. I remember like it was yesterday, the first Walk and the passion that I saw in all the walkers faces as I greeted them at the Finish Line. I was so grateful for all that they had done and the amazing funds that each walker raised to support the work at the Princess Margaret Cancer Centre.

In the last many years we have accomplished so much together.

For example, the Cancer Centre created the first in-hospital survivorship program which was originally for breast cancer patients, but subsequently was expanded so that all patients could take advantage of this support program.

My scientific discovery team and I began the long journey to find new targets over a decade ago, and today, we have several novel therapies that have moved into clinical trials. To accomplish this, we created a new Therapeutics Group within the Campbell Family Institute at the Princess Margaret Cancer Centre. One drug known as PLK 4 has completed Phase 1 trials and is moving into Phase 2. A second drug known as TTK is moving into Phase 1 trials. The road for new therapies and true breakthroughs take time and ongoing funding. We also have other discoveries in the pipeline and therapeutics under-development which we are hoping to further advance in 2017.

Another major accomplishment has been the creation of the Tumor Immunotherapy Program. Drs. Lillian Siu and Pam Ohashi are Co-Directors of this program. The walkers supported our discovery work in Immunotherapy from the beginning. Today, it is one of the biggest ideas of the past decade and we believe it has the potential to revolutionize cancer therapy. This could be the fourth pillar of cancer treatment in addition to surgery, radiation and chemotherapy. We now have over 180 active clinical trials underway including Canada’s first gene-engineered T-cell trial. The Princess Margaret, in part to Walker community, now boasts Canada’s most comprehensive immunotherapy program. This work could be effective on a number of different types of cancer and even some of the more difficult to treat today.

As we continue on our journey, know that progress is being made. We understand so much more today than when I started my career in the 70’s. We are in an amazing era of genomic discovery and uncovering insights that have eluded researchers in previous decades. We now know that there are many forms of cancer within the same type and that some forms of one cancer are more related to another form of cancer. We are discovering new cancer targets and from that new targeted therapies.

So I encourage you to Walk in the Rexall OneWalk to Conquer Cancer to allow me and my fellow researchers to continue our work. I share your passion and your dream that one day all cancers not be a disease that you die from, but a disease that can be controlled and that you live with.

The team at the Princess Margaret Cancer Centre is committed but we can’t do it alone.

I will see you on the 2017 Walk, please make sure to come up and introduce yourself!

My heartfelt thanks,

Dr. Tak Mak
Director, The Campbell Family Cancer Research Institute
Princess Margaret Cancer Centre

We’ve passed the halfway point in our BILLION DOLLAR CHALLENGE… and we’re getting closer.

Conquering cancer in our lifetime is a bold vision, and one that will have a huge impact. More than 40 percent of Canadians will be diagnosed with some type of cancer, so it is vital that we develop more effective treatments and continue research that will lead to a new understanding of how the disease begins and spreads.

Today, thanks to research, over 50 percent of all cancer patients live ten years or more (in the 1970s, it was 25 percent). For some types of cancers—breast, prostate and many types of lymphoma and sarcoma—the long-term survival rates are 80 percent or higher. But for other types—lung, pancreatic and ovarian—the rates remain persistently low. That is because they are all different diseases and need specially-designed diagnostic and treatment approaches.

As one of the top 5 cancer research centres in the world, the scientists and clinicians at Princess Margaret Cancer Centre are creating tomorrow’s cancer treatment today—one disease at a time. They are conducting over 700 clinical studies of new treatment approaches, and they have a responsibility to share their success and their insight about the disease with other cancer specialists in Canada and the world. Our job is to ensure they have the equipment and the support to do their life-saving work.

At The Princess Margaret Cancer Foundation, we don’t shy away from bold visions that require big funding. In April 2012, we launched a bold BILLION DOLLAR CHALLENGE to raise the funds needed to create a new gold standard of cancer care: Personalized Cancer Medicine. We have now passed the halfway point in the challenge and have secured $576 million through philanthropy and research grants.

Personalized Cancer Medicine will include new diagnostic and treatment approaches that reflect the reality that each person’s cancer is unique and each cancer patient is a unique individual. There are already over 200 documented types of cancer, and even when two people have the same type, it varies in size, position and potential to spread. And each patient’s ability to tolerate treatment is different.

We all have a reason to support the BILLION DOLLAR CHALLENGE. Cancer will impact you or a family member, a friend or close colleague. Thank you to all of our donors who have contributed to the challenge so far. We still have a long way to go, but we know that so many share our vision of a world where cancer is controlled and prevented. We hope we can count on your continued support.

Tom Ehrlich


Chair, Board of Directors

What is Personalized Cancer Medicine?

At The Princess Margaret, we are excited to be leading a new integrated approach to cancer treatment called Personalized Cancer Medicine.

This approach will include using a patient’s genetic information to more precisely diagnose their cancer and tailor the most effective treatment for them.

But Personalized Cancer Medicine at The Princess Margaret is so much more. We have always focused on the individual needs of each patient and not just their disease.

That is why we have:

  • Developed award-winning clinical programs to assist our patients and their families
  • Recruited highly-skilled physicians and scientists who have the expertise to lead important research projects and clinical studies that improve the standard of care for patients
  • Built integrated teams that include engineers, bioinformatics specialists and medicinal chemists. These teams are translating new technology and discoveries into improved therapies that will help more patients sooner

Our strong culture of innovation has made this cancer centre a world leader in cancer research and treatment, and with your financial support, we will lead the way in Personalized Cancer Medicine.

Dr. Mary Gospodarowicz, Medical Director

What is Personalized Cancer Medicine?

Over the past 50 years, our scientists and physicians have learned just how complex cancer is. Every patient and every patient’s cancer is unique.

There has been a clear understanding for some time that cancer is a very different disease depending on where it originates. So today lung cancer is treated in a different way than colon or kidney cancer, or leukemia.

But more recently, new technology and insight have allowed us to see that the disease is even more complex than that. There can be many forms of lung cancer or colon cancer, and a genetic analysis of a tumour may be required to confirm the specifics of each patient’s disease.

The Princess Margaret is one of the top 5 cancer research centres in the world with an outstanding reputation for breakthrough research, exemplary teaching and compassionate care.

We are two years into our Billion Dollar Challenge, which is a five-year initiative to help revolutionize cancer care. Over the next three years, The Princess Margaret will continue to be creating the blueprint, developing and implementing new procedures, and setting the gold standard for Personalized Cancer Medicine for all patients at The Princess Margaret, across Canada and around the world. In addition to genetic analysis of tumours, this new approach to cancer treatment encompasses four main themes:

  • Detect
  • Diagnose
  • Target
  • Support

Detecting cancer earlier

If cancer is detected at an early stage, the prognosis for a complete remission is much improved. Our research teams are working on many early detection initiatives, including:

  • Developing and testing better imaging equipment so small tumours can be seen more clearly
  • Identifying unique ‘markers’ of cancers that can be detected in blood and serum tests

Diagnosing with more precision

New equipment and procedures that determine the specific genetic mutations or changes that gave rise to a patient’s cancer are being tested at The Princess Margaret. This information will enable the experts to recommend the optimal combination of drug and other therapies for successfully treating each patient.

Targeting treatment for each patient

Improved surgical, radiation and drug treatments will target only the cancer and leave healthy tissue alone, minimizing toxic side effects. Our scientists and doctors are testing new treatments that can more effectively detect and eradicate cancer cells leading to more durable cures.

Supporting patients and families throughout their cancer journey

Being well-informed about their disease, the treatment they will receive and the side effects that can be expected gives patients and their families more confidence, reduces anxiety and leads to improved quality of life. Our award-winning survivorship, patient education and psychosocial support programs need to be expanded so that more patients can be empowered throughout their personal cancer journey.

Princess Margaret Cancer Centre

About Princess Margaret Cancer Centre

Princess Margaret Cancer Centre is one of the top 5 cancer research centres in the world. We are the largest cancer research and clinical program in Canada. As global leaders in cancer care, we have the expertise to treat over 200 types of cancers, including the rarest forms of the disease. The Princess Margaret has a rich history of research excellence, discovery and innovation. Every day, we combine our clinical strength with the research expertise of The Campbell Family Cancer Research Institute to deliver breakthrough cancer research, treatments and patient-centered care.

Because we are Canada’s largest and most comprehensive cancer research centre, The Princess Margaret is responsible for delivering the evidence and measuring the benefit of new treatments and new approaches. We are proud to lead the way in the creation and delivery of the new gold standard in cancer care: Personalized Cancer Medicine.

The Princess Margaret is

  • A world leader in image-guided therapeutics.
  • A world leader in lung cancer research and treatment.
  • A world leader in patient survivorship program development.
  • An emerging world leader in breast cancer research and discovery.
  • An emerging world leader in immune therapy.
  • An emerging world leader in palliative care and support research.
  • An emerging world leader in Personalized Cancer Medicine.

The Princess Margaret offers comprehensive cancer care across 13 disease sites: Breast, Lung, Gastrointestinal, Gynecologic, Genitourinary, Head and Neck, Central Nervous System, Lymphoma, Sarcoma, Leukemia, Eye, Melanoma, Thyroid

2016 By the Numbers:

  • The Princess Margaret treats over 200 types of cancer through surgery, chemotherapy, radiation, psychosocial and palliative care.
  • Total new patients: 17,751
  • Outpatient Clinic Visits: 228,380
  • Systemic Therapy Treatments: 37,750
  • Radiation Treatments: 91,517
  • Cancer Surgeries: 6,031
  • Stem Cell Transplants: 428
  • Patients Participating in Clinical Research Studies: 7,144 with 1,956 entered into clinical trials.
  • For more information, review the Princess Margaret Cancer Centre Annual Report.

The Princess Margaret Cancer Centre has achieved an international reputation as a global leader in the fight against cancer and delivering Personalized Cancer Medicine. The Princess Margaret, one of the top 5 cancer research centres in the world, is a member of the University Health Network, which also includes Toronto General Hospital, Toronto Western Hospital and Toronto Rehabilitation Institute. All are research hospitals affiliated with the University of Toronto. www.theprincessmargaret.ca

Princess Margaret Cancer Centre

About The Campbell Family Cancer Research Institute

Vision

The Campbell Family Cancer Research Institute is recognized as one of the top 5 cancer research facilities in the world as measured by its number of new discoveries, the quality of its research, its reputation and its overall impact on conquering cancer in our lifetime.

Values

  • Scientific excellence
  • Relevance of research to the clinic
  • Ability to bridge disciplines
  • Dedication
  • Creativity

Background

The Campbell Family Institute for Breast Cancer Research was launched in June 2004 thanks to an extraordinarily generous gift of $25 million from the late Audrey Campbell and her three daughters. In addition, Susan Grange donated $5 million to support the innovative work of Dr. David Jaffray in the area of image-guided radiation.

The Campbell Family Cancer Research Institute, supported by the significant and long-term commitment of the Campbell Family and The Walk, is an international powerhouse at the Princess Margaret Cancer Centre. The Campbell Family Cancer Research Institute leads the world in many of the most promising areas of cancer research such as tumour metabolism, cancer stem cells, cancer genomics, proteomics, informatics and molecular imaging/guided therapeutics. The Campbell Family Institute builds on the breast cancer research work of internationally recognized Dr. Tak Mak and his team to benefit all cancers.

The sustainable development of The Campbell Family Institute will depend on the close integration of people and resources, enabling maximum global impact in the fight against cancer.

The Campbell Family Cancer Research Institute capitalizes on the work of existing stars, such as Dr. Tak Mak (t-cell receptor discovery and more recent new cancer target discovery), Dr. John Dick (cancer stem cells) and Dr. Pam Oashi (immune therapy) and a long list of distinguished researchers, to accelerate the pace of cancer research, facilitating the translation of scientific advances into new life-saving therapies that will help us in our collective efforts to CONQUER CANCER IN OUR LIFETIME.

The vision of The Campbell Family Cancer Research Institute is to continue to be recognized as one of the top 5 cancer research centres in the world as measured by its number of new discoveries, the quality of its research, its reputation and its overall impact on conquering cancer.

For more information go to: www.campbellfamilyinstitute.ca

Princess Margaret Cancer Centre

The Princess Margaret’s Billion Dollar Challenge

The Challenge is a 5-year initiative to secure $1 BILLION to create the new gold standard in cancer care: PERSONALIZED CANCER MEDICINE.

This new approach to cancer care involves finding the right treatment, for the right patient, at the right time. Our focus is to detect cancer earlier, diagnose with more precision, target treatment for each individual and support patients and their families through their cancer journey.

The Billion Dollar Challenge supports this ambitious goal. The Princess Margaret Cancer Foundation’s challenge is to raise $500 million through philanthropy over this period while our researchers are challenged to secure $500 million in research grants. We are tracking ahead of plan, but every donation, every Walker and every program counts as we seek to accomplish this goal.

We are enormously grateful to all those who support our vision of Personalized Cancer Medicine. To create and deliver this new model of cancer care, leaders at The Princess Margaret are recruiting scientists, clinicians and other experts to further strengthen our position in important areas such as epigenetics, clinical genomics, bio banking, computational biology, immune therapy and pathology.

The Billion Dollar Challenge will help ensure that Princess Margaret Cancer Centre remains one of the top 5 cancer research centres in the world and leads the way in new therapies to save more lives for patients at The Princess Margaret, across Canada and around the world.

Princess Margaret Cancer Centre

Immunotherapy at The Princess Margaret - Revolutionizing Cancer Therapy

Immunotherapy is rapidly gaining recognition for its potential to change the way we treat cancer and to join chemotherapy, radiation and surgery as a fourth pillar of cancer treatment.

Within the international scientific community, it has been long understood that the immune system has the ability to conquer cancer. We’re now at a point where this knowledge has started to become translated into treatment possibilities for cancer patients.

We have already seen numerous success stories of cancers fought and lives extended through immunotherapy.

This vital research is made possible in part by donations received from more than 62,000 participants who have Walked The Walk! Because of OneWalk, we are advancing cancer research.Learn more about the vital work being done at The Princess Margaret to revolutionize immunotherapy treatment by clicking here.

To read The Princess Margaret's Immunotherapy Magazine, click here.